Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly six months since my last Aquestive Therapeutics (NASDAQ: AQST ) article , where I discussed five areas of focus for the company in 2025, including Anaphylm's potential FDA approval. Since then, the ticker is down roughly 2%, but the c ...